SCHEDULE: Silo Pharma: Intracoastal Group Maintains 9.99% Stake

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a continued beneficial ownership of 9.99% in Silo Pharma, Inc. common stock as of September 30, 2025.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") beneficially own 1,384,410 shares of Silo Pharma, Inc. common stock.
• This ownership represents approximately 9.99% of the company's common stock.
• The beneficial ownership consists of 844,725 shares directly held by Intracoastal Capital LLC and 539,685 shares issuable upon the exercise of Intracoastal Warrant 1.
• The calculation of the 9.99% stake is based on 13,318,273 shares of common stock outstanding as of September 30, 2025, plus the 539,685 shares from Intracoastal Warrant 1.
• Multiple warrants held by Intracoastal Capital LLC (Intracoastal Warrants 1, 2, 3, 4, and 5) contain blocker provisions that prevent their exercise if it would result in beneficial ownership exceeding 9.99% or 4.99% of the common stock.
• Without these blocker provisions, the Reporting Persons would have been deemed to beneficially own 4,189,630 shares of common stock.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of beneficial ownership. The reporting persons maintain a significant 9.99% stake in Silo Pharma, which can be viewed as a positive signal of continued investor interest. However, the presence of blocker provisions on multiple warrants limits immediate exercisability and potential influence, making the sentiment largely neutral.

Positives

• The continued significant institutional ownership by Intracoastal Capital LLC and its affiliates, maintaining a 9.99% stake, indicates sustained investor interest in Silo Pharma, Inc.

Negatives

• The presence of blocker provisions on multiple warrants limits the immediate exercisability of a substantial portion of potential shares, which could restrict the Reporting Persons' ability to increase their stake or influence company decisions beyond the 9.99% threshold.

Risks

• The existence of blocker provisions on five different warrants means that a large number of shares (an additional 2,805,220 shares beyond the currently counted 1,384,410) are not immediately exercisable if such exercise would cause the beneficial ownership to exceed the specified thresholds (9.99% or 4.99%). This could impact future capital structure and control dynamics if these provisions were to be removed or waived.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Silo Pharma, Inc.'s operational or financial performance.

Industry Context

This Schedule 13G filing reflects a significant passive investment by an institutional group in Silo Pharma, Inc., a company likely operating in the pharmaceutical or biotechnology sector. Such disclosures are standard for institutional investors acquiring or maintaining substantial, non-controlling equity stakes in publicly traded companies.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional shareholder's stake. The continued holding of a 9.99% stake by Intracoastal Capital LLC and its affiliates may be viewed positively, indicating confidence. The existence of warrants, even with blockers, represents potential future dilution if exercised.
• Company Management: Awareness of a significant, albeit passive, institutional investor group and their potential future shareholdings.

Key Dates

Recommendation

This filing is a routine Schedule 13G amendment disclosing a significant, but stable, beneficial ownership stake. It does not contain new operational or financial information about Silo Pharma that would warrant a change in investment thesis. The continued 9.99% stake by Intracoastal Capital LLC and its affiliates, along with the details of their warrant holdings, suggests a long-term, passive investment strategy. Investors should hold their position and look for further operational updates from Silo Pharma for any changes in recommendation.

Keywords

Silo Pharma, Intracoastal Capital, Mitchell Kopin, Daniel Asher, Schedule 13G, beneficial ownership, common stock, warrants, equity stake, institutional investor, blocker provisions